Better computer ranking of medicine pairs for DIPG
- Good it would do
- 2 / 5
- Can AI help
- 3 / 5
- How neglected
- 2 / 5
- Can we check it
- 4 / 5
Why we stopped
Rejected on prior art and target validity: in-dish synergy, the label a pair ranking would learn, has not predicted benefit in animal models in this disease or pan-cancer; public combination data are essentially one cell line around two anchor drugs; and funded groups with labs already design combinations by other methods. One narrow open benchmark survives but was judged too narrow; the brain-exposure route stays under parked problem 9.
Why it's stuck
A 2020 repurposing study found only moderate agreement between computer predictions and lab results, and blamed weak brain-permeability modeling and bias in the literature it learned from. Few groups have followed up.
What we'd try
Redo the search with better permeability models and patient-derived data, then hand a ranked list to lab partners.
Source: https://www.biorxiv.org/content/10.1101/2020.06.14.150714v3.full
Think we got it wrong?
Ruled-out problems can come back. Tell us what we missed.
Members can read the full record for this problem, check its sources and comment. Open the member view →